Emmanuel Zorn1, Sarah B See. 1. Columbia Center for Translational Immunology, Columbia University Medical Center, New York, New York, USA.
Abstract
PURPOSE OF REVIEW: Antibody-mediated rejection (ABMR), especially in its chronic manifestation, is increasingly recognized as a leading cause of late graft loss following solid organ transplantation. In recent years, autoantibodies have emerged as a significant component of the humoral response to allografts alongside anti-human leukocyte antigen antibodies. These include polyreactive antibodies also known as natural antibodies (Nabs) secreted by innate B cells. A hallmark of Nabs is their capacity to bind altered self such as oxidized lipids on apoptotic cells. This review provides an overview of these overlooked antibodies and their implication in the pathophysiology of ABMR. RECENT FINDINGS: New evidence reported in the past few years support a contribution of immunoglobulin (Ig) G Nabs to ABMR. Serum IgG Nabs levels are significantly higher in patients with ABMR compared with control kidney transplant recipients with stable graft function. Pretransplant IgG Nabs are also associated with ABMR and late graft loss. IgG Nabs are almost exclusively of the IgG1 and IgG3 subclasses and have the capacity to activate complement. SUMMARY: In conclusion, Nabs are important elements in host immune responses to solid organ grafts. The recent description of their implication in ABMR and late kidney graft loss warrants further investigation into their pathogenic potential.
PURPOSE OF REVIEW: Antibody-mediated rejection (ABMR), especially in its chronic manifestation, is increasingly recognized as a leading cause of late graft loss following solid organ transplantation. In recent years, autoantibodies have emerged as a significant component of the humoral response to allografts alongside anti-human leukocyte antigen antibodies. These include polyreactive antibodies also known as natural antibodies (Nabs) secreted by innate B cells. A hallmark of Nabs is their capacity to bind altered self such as oxidized lipids on apoptotic cells. This review provides an overview of these overlooked antibodies and their implication in the pathophysiology of ABMR. RECENT FINDINGS: New evidence reported in the past few years support a contribution of immunoglobulin (Ig) G Nabs to ABMR. Serum IgG Nabs levels are significantly higher in patients with ABMR compared with control kidney transplant recipients with stable graft function. Pretransplant IgG Nabs are also associated with ABMR and late graft loss. IgG Nabs are almost exclusively of the IgG1 and IgG3 subclasses and have the capacity to activate complement. SUMMARY: In conclusion, Nabs are important elements in host immune responses to solid organ grafts. The recent description of their implication in ABMR and late kidney graft loss warrants further investigation into their pathogenic potential.
Authors: Maryvonne Hourmant; Anne Cesbron-Gautier; Paul I Terasaki; Kazuo Mizutani; Anne Moreau; Aurélie Meurette; Jacques Dantal; Magali Giral; Gilles Blancho; Diego Cantarovich; Georges Karam; Gilles Follea; Jean-Paul Soulillou; Jean-Denis Bignon Journal: J Am Soc Nephrol Date: 2005-07-13 Impact factor: 10.121
Authors: Andrew Elvington; Carl Atkinson; Liudmila Kulik; Hong Zhu; Jin Yu; Mark S Kindy; V Michael Holers; Stephen Tomlinson Journal: J Immunol Date: 2011-12-23 Impact factor: 5.422
Authors: Michael S Haas; Elisabeth M Alicot; Franziska Schuerpf; Isaac Chiu; Jinan Li; Francis D Moore; Michael C Carroll Journal: Cardiovasc Res Date: 2010-05-11 Impact factor: 10.787
Authors: Sherry D Fleming; Ryan P Egan; Chunyan Chai; Guillermina Girardi; V Michael Holers; Jane Salmon; Marc Monestier; George C Tsokos Journal: J Immunol Date: 2004-12-01 Impact factor: 5.422
Authors: Leora B Balsam; G Kimia Mokhtari; Sophie Jones; Shannon Peterson; E Grant Hoyt; Theo Kofidis; Masashi Tanaka; David T Cooke; Robert C Robbins Journal: J Heart Lung Transplant Date: 2005-07 Impact factor: 10.247
Authors: Nancy L Reinsmoen; Chih-Hung Lai; James Mirocha; Kai Cao; Geraldine Ong; Mehrnoush Naim; Qi Wang; Mark Haas; Matthew Rafiei; Lawrence Czer; Jignesh Patel; Jon Kobashigawa Journal: Transplantation Date: 2014-03-15 Impact factor: 4.939
Authors: Carolina Moore; Baoshan Gao; Krishna M Roskin; Elena-Rodica M Vasilescu; Linda Addonizio; Michael M Givertz; Joren C Madsen; Emmanuel Zorn Journal: Am J Transplant Date: 2019-12-27 Impact factor: 8.086
Authors: Mélanie Dieudé; Lori J West; Daniel A Muruve; Lakshman Gunaratnam; Thalachallour Mohanakumar; Emmanuel Zorn; Christopher W Cairo; Darren H Freed; Kirk R Schultz; Robert L Fairchild; Marie-Josée Hébert Journal: Transplantation Date: 2018-02 Impact factor: 4.939
Authors: Sergi Clotet-Freixas; Max Kotlyar; Caitriona M McEvoy; Chiara Pastrello; Sonia Rodríguez-Ramírez; Sofia Farkona; Heloise Cardinal; Mélanie Dieudé; Marie-Josée Hébert; Yanhong Li; Olusegun Famure; Peixuen Chen; S Joseph Kim; Emilie Chan; Igor Jurisica; Rohan John; Andrzej Chruscinski; Ana Konvalinka Journal: Transplant Direct Date: 2021-09-20
Authors: Nicole M van Besouw; Aleixandra Mendoza Rojas; Sarah B See; Ronella de Kuiper; Marjolein Dieterich; Dave L Roelen; Marian C Clahsen-van Groningen; Dennis A Hesselink; Emmanuel Zorn; Carla C Baan Journal: J Transplant Date: 2021-09-30
Authors: K Böröcz; D Simon; S Erdő-Bonyár; K T Kovács; É Tuba; L Czirják; P Németh; T Berki Journal: Clin Exp Immunol Date: 2020-10-13 Impact factor: 4.330